Antiviral Treatment Guidelines for Middle East Respiratory Syndrome
Open Access
- 1 January 2015
- journal article
- review article
- Published by XMLink in Infection & Chemotherapy
- Vol. 47 (3) , 212-222
- https://doi.org/10.3947/ic.2015.47.3.212
Abstract
Chong YP, et al. Infect Chemother. 2015 Sep;47(3):212-222. http://dx.doi.org/10.3947/ic.2015.47.3.212Keywords
This publication has 42 references indexed in Scilit:
- Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapyInternational Journal of Infectious Diseases, 2013
- MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatmentJournal of General Virology, 2013
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinScientific Reports, 2013
- Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and CoronavirusClinical Infectious Diseases, 2012
- Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosisNeurology, 2010
- Corticosteroid treatment of severe acute respiratory syndrome in Hong KongJournal of Infection, 2007
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Common Adverse Events Associated with the Use of Ribavirin for Severe Acute Respiratory Syndrome in CanadaClinical Infectious Diseases, 2003